中国美容医学2011，Vol.20Issue(z5)：37,1.
吉非替尼联合艾迪注射液治疗晚期非小细胞肺癌的临床观察
张纪良 1刘定义 1陈济 1陈萍 1朱丽 1刘鸿1
作者信息
- 1. 四川省成都市第七人民医院肿瘤科 610021
- 折叠
摘要
Abstract
Objective:This study evaluated the efficacy and toxicity of Gefitnib combination with aidi injection in treatment of advanced non—small — cell lung cancer. Methods:44 patients with advanced non—small —cell lung cancer were randomly divided into two groups. The treatment group 22 cases and the control group 22 cases. The treatment group(n=22) was treated with gefitnib and aidi injection. Gefitinib was orally administered 25Omg/d and aidi injection iv 50ml/d. The control group(n=22) was treated with gefitnib 25Omg/d alone. Results:Response rate and toxicity were assessed in all the 44 patients. The response rate was 40. 9% in the treatment group and 27. 3% in the control group respectively. The disease control rate was 86. 4% for the treatment group and 59.1% for the control group. The disease control rate in the two groups showed statistically significant difference(P<0. 05). The main toxicity were grade I or II rash and diarrhea which was generally tolerable. Conclusion:Gefitnib combination with aidi injection could enhance the curative effect and reduce the relevant treatment side effects in treatment of advanced non—small—cell—lung cancer.关键词
吉非替尼/艾迪注射液/非小细胞肺癌Key words
Adye inoculation fluid/Non—cellule lung cancer分类
医药卫生引用本文复制引用
张纪良,刘定义,陈济,陈萍,朱丽,刘鸿..吉非替尼联合艾迪注射液治疗晚期非小细胞肺癌的临床观察[J].中国美容医学,2011,20(z5):37,1.
